Search research articles
Contact Us
Filters
Showing results (151-160 of 189) with videos related to
Page
of 19
Sort By:
Molecular and Clinical Oncology
|
May 19, 2017
Programmed death-ligand 1 expression is associated with fibrosarcomatous transformation of dermatofibrosarcoma protuberans
Kenji Tsuchihashi, Hitoshi Kusaba, Yuichi Yamada, et al.
Scientific Reports
|
May 31, 2023
C-reactive protein/albumin ratio is the most significant inflammatory marker in unresectable pancreatic cancer treated with FOLFIRINOX or gemcitabine plus nab-paclitaxel
Tsuyoshi Shirakawa, Akitaka Makiyama, Mototsugu Shimokawa, et al.
Nature Communications
|
October 19, 2024
Spatial dynamics of CD39<sup>+</sup>CD8<sup>+</sup> exhausted T cell reveal tertiary lymphoid structures-mediated response to PD-1 blockade in esophageal cancer
Kenro Tanoue, Hirofumi Ohmura, Koki Uehara, et al.
ESMO Open
|
March 14, 2018
Chemotherapy in cancer patients undergoing haemodialysis: a nationwide study in Japan
Taro Funakoshi, Takahiro Horimatsu, Michio Nakamura, et al.
Cancer Research
|
March 17, 2016
The EGF Receptor Promotes the Malignant Potential of Glioma by Regulating Amino Acid Transport System xc(-)
Kenji Tsuchihashi, Shogo Okazaki, Mitsuyo Ohmura, et al.
Cancer Science
|
August 25, 2018
Epithelial-mesenchymal transition is activated in CD44-positive malignant ascites tumor cells of gastrointestinal cancer
Michitaka Nakano, Mamoru Ito, Risa Tanaka, et al.
Clinical Immunology (Orlando, Fla.)
|
April 14, 2016
Phase I clinical trial of a five-peptide cancer vaccine combined with cyclophosphamide in advanced solid tumors
Mutsunori Murahashi, Yasuki Hijikata, Kazunari Yamada, et al.
BMC Cancer
|
April 12, 2025
A phase I/II trial evaluating the safety of increased-dose S- 1 with oxaliplatin and nivolumab in HER2-negative advanced gastric cancer
Keisuke Baba, Nobumi Suzuki, Chiyo K Imamura, et al.
International Journal of Clinical Oncology
|
July 21, 2022
Primary tumor location as a predictor of survival in patients with RAS wild-type colorectal cancer who receive molecularly targeted drugs as first-line therapy: a multicenter real-world observational study by the Japanese Society for Cancer of the Colon and Rectum
Takahiko Ito, Atsuo Takashima, Kentaro Yamazaki, et al.
International Journal of Clinical Oncology
|
August 28, 2024
Real-world outcomes of FOLFOXIRI plus bevacizumab in patients with metastatic colorectal cancer: the JSCCR-TRIPON study
Yoshiyuki Yamamoto, Hiroki Yukami, Tatsuro Yamaguchi, et al.
Page
of 19
Search research articles
Search
Showing results (151-160 of 189) with videos related to
Sort By:
Page
of 19
Molecular and Clinical Oncology
|
May 19, 2017
Programmed death-ligand 1 expression is associated with fibrosarcomatous transformation of dermatofibrosarcoma protuberans
Kenji Tsuchihashi, Hitoshi Kusaba, Yuichi Yamada, et al.
Scientific Reports
|
May 31, 2023
C-reactive protein/albumin ratio is the most significant inflammatory marker in unresectable pancreatic cancer treated with FOLFIRINOX or gemcitabine plus nab-paclitaxel
Tsuyoshi Shirakawa, Akitaka Makiyama, Mototsugu Shimokawa, et al.
Nature Communications
|
October 19, 2024
Spatial dynamics of CD39<sup>+</sup>CD8<sup>+</sup> exhausted T cell reveal tertiary lymphoid structures-mediated response to PD-1 blockade in esophageal cancer
Kenro Tanoue, Hirofumi Ohmura, Koki Uehara, et al.
ESMO Open
|
March 14, 2018
Chemotherapy in cancer patients undergoing haemodialysis: a nationwide study in Japan
Taro Funakoshi, Takahiro Horimatsu, Michio Nakamura, et al.
Cancer Research
|
March 17, 2016
The EGF Receptor Promotes the Malignant Potential of Glioma by Regulating Amino Acid Transport System xc(-)
Kenji Tsuchihashi, Shogo Okazaki, Mitsuyo Ohmura, et al.
Cancer Science
|
August 25, 2018
Epithelial-mesenchymal transition is activated in CD44-positive malignant ascites tumor cells of gastrointestinal cancer
Michitaka Nakano, Mamoru Ito, Risa Tanaka, et al.
Clinical Immunology (Orlando, Fla.)
|
April 14, 2016
Phase I clinical trial of a five-peptide cancer vaccine combined with cyclophosphamide in advanced solid tumors
Mutsunori Murahashi, Yasuki Hijikata, Kazunari Yamada, et al.
BMC Cancer
|
April 12, 2025
A phase I/II trial evaluating the safety of increased-dose S- 1 with oxaliplatin and nivolumab in HER2-negative advanced gastric cancer
Keisuke Baba, Nobumi Suzuki, Chiyo K Imamura, et al.
International Journal of Clinical Oncology
|
July 21, 2022
Primary tumor location as a predictor of survival in patients with RAS wild-type colorectal cancer who receive molecularly targeted drugs as first-line therapy: a multicenter real-world observational study by the Japanese Society for Cancer of the Colon and Rectum
Takahiko Ito, Atsuo Takashima, Kentaro Yamazaki, et al.
International Journal of Clinical Oncology
|
August 28, 2024
Real-world outcomes of FOLFOXIRI plus bevacizumab in patients with metastatic colorectal cancer: the JSCCR-TRIPON study
Yoshiyuki Yamamoto, Hiroki Yukami, Tatsuro Yamaguchi, et al.
Page
of 19